The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database
- PMID: 24726734
- DOI: 10.1016/j.ejca.2014.03.014
The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database
Abstract
Purpose: Progressive disease (PD) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 is defined as growth of measurable target lesions, presence of new lesions or unequivocal progression of non-target disease. In this manuscript we explored whether a more refined categorisation of tumour response and/or these components of progression, varying over time, can improve prediction of overall survival (OS) in the RECIST database.
Methods: Data were randomly selected from 13 randomised clinical trials (3758 patients with breast, lung or colorectal cancer). A maximum of five target lesions contributed to the sum of longest diameters. At each measurement time we determined: best target response as best % improvement from baseline; tumour growth of target lesions as worst % change and worst rate of increase (mm/week) from nadir; presence of new lesions and occurrence of non-target PD. OS was analysed by tumour type using Cox regression, adjusting for baseline sum and including these parameters as time-dependent covariates.
Results: 36% of patients had new lesions, 28% non-target PD and 49% experienced target lesion growth (median strongest growth 1.5mm/week). Regardless of tumour type, presence of new lesions (hazard ratio (HR) ranging 1.5-2.3) and non-target PD (HR 1.5-2.0) were strongly associated with worse OS. The explanatory value of tumour growth for OS was low compared to the other components.
Conclusion: Modelling target lesion tumour growth did not show a marked improvement in OS prediction over and above the other components. These analyses enable a better understanding of the role of each component in PD evaluation. Work is ongoing to incorporate this information into an updated version of RECIST with enhanced prediction of subsequent survival.
Keywords: Breast cancer; Colorectal cancer; Goodness-of-fit; Lung cancer; Time-dependent model; Tumour growth.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Comment in
-
Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.).Eur J Cancer. 2014 Nov;50(16):2887-8. doi: 10.1016/j.ejca.2014.07.026. Epub 2014 Sep 15. Eur J Cancer. 2014. PMID: 25218336 No abstract available.
-
Reply to Verlingue, Koscielny and Ferté.Eur J Cancer. 2014 Nov;50(16):2889-91. doi: 10.1016/j.ejca.2014.08.001. Epub 2014 Sep 15. Eur J Cancer. 2014. PMID: 25219450 No abstract available.
-
Non-target progression--the fine line between objectivity and subjectivity.Eur J Cancer. 2014 Dec;50(18):3271-2. doi: 10.1016/j.ejca.2014.08.021. Epub 2014 Oct 18. Eur J Cancer. 2014. PMID: 25450948 No abstract available.
Similar articles
-
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse.J Clin Oncol. 2014 Mar 10;32(8):841-50. doi: 10.1200/JCO.2013.52.3019. Epub 2014 Feb 10. J Clin Oncol. 2014. PMID: 24516033 Free PMC article.
-
Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival.J Natl Cancer Inst. 2015 Aug 21;107(11):djv239. doi: 10.1093/jnci/djv239. Print 2015 Nov. J Natl Cancer Inst. 2015. PMID: 26296640 Free PMC article.
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. Eur J Cancer. 2009. PMID: 19097774
-
The prognostic value of AGR2 expression in solid tumours: a systematic review and meta-analysis.Sci Rep. 2017 Nov 14;7(1):15500. doi: 10.1038/s41598-017-15757-z. Sci Rep. 2017. PMID: 29138453 Free PMC article.
-
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).Eur J Cancer. 2015 Sep;51(14):1927-36. doi: 10.1016/j.ejca.2015.06.116. Epub 2015 Jul 15. Eur J Cancer. 2015. PMID: 26188850 Review.
Cited by
-
PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies.Aging (Albany NY). 2020 Jan 24;12(2):1577-1590. doi: 10.18632/aging.102701. Epub 2020 Jan 24. Aging (Albany NY). 2020. PMID: 31980592 Free PMC article.
-
Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.J Transl Med. 2018 Mar 9;16(1):54. doi: 10.1186/s12967-018-1443-5. J Transl Med. 2018. PMID: 29523158 Free PMC article.
-
Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.Front Oncol. 2022 Jan 10;11:800547. doi: 10.3389/fonc.2021.800547. eCollection 2021. Front Oncol. 2022. PMID: 35083155 Free PMC article.
-
The mode of progressive disease affects the prognosis of patients with metastatic breast cancer.World J Surg Oncol. 2018 Aug 14;16(1):169. doi: 10.1186/s12957-018-1472-9. World J Surg Oncol. 2018. PMID: 30107807 Free PMC article.
-
A call for objectivity: Radiologists' proposed wishlist for response evaluation in solid tumors (RECIST 1.1).Cancer Imaging. 2024 Nov 14;24(1):154. doi: 10.1186/s40644-024-00802-8. Cancer Imaging. 2024. PMID: 39543673 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical